株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオチップの世界市場:マイクロアレイとラボオンチップ (LOAC:LAB-ON-A-CHIP)

Global Biochip Markets: Microarrays and Lab-on-a-Chip

発行 BCC Research 商品コード 208743
出版日 ページ情報 英文 408 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
バイオチップの世界市場:マイクロアレイとラボオンチップ (LOAC:LAB-ON-A-CHIP) Global Biochip Markets: Microarrays and Lab-on-a-Chip
出版日: 2016年04月21日 ページ情報: 英文 408 Pages
概要

2014年、世界のバイオチップ製品の市場は39億米ドルに近い規模を記録しました。2015年から2020年にかけては31.6%のCAGR (年間複合成長率) で推移し、2015年の47億米ドルから、2020年には184億米ドルの規模に成長すると予測されています。

当レポートでは、世界のバイオチップ産業を調査し、技術および製品の種類と概要、技術の発展状況、市場成長への各種影響因子の分析、薬剤開発および診断部門における各種用途、市場規模の推移と予測、企業および企業間の取り組み、特許データ、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • イントロダクション
  • バイオチップの種類
  • バイオチップの市場潜在性
  • バイオチップ市場の成長因子
  • バイオチップ産業

第4章 マイクロアレイ技術

  • イントロダクション
  • DNAマイクロアレイ技術
  • プロテインマイクロアレイ技術
  • 新興マイクロアレイ技術

第5章 ラボオンチップ (LOAC:LAB-ON-A-CHIP) 技術

  • イントロダクション
  • 基板材料
  • LOACの種類
  • LOACの用途
  • ORGAN ON CHIP
  • LOACの技術的課題

第6章 創薬および新薬開発用途

  • イントロダクション
  • 医薬品産業の課題
  • 創薬および新薬開発プロセス
  • 創薬および新薬開発プロセスにおけるニーズ

第7章 診断用途

  • イントロダクション
  • 研究ツールとの違い
  • バイオロジカルコンテンツによる診断部門の成長の推進
  • バイオマーカー検査の臨床的需要への影響因子
  • 分子診断
  • 診断市場部門
  • 試験の感受性と特異性
  • 法規制動向
  • ワルファリン感受性
  • 感染症
  • 神経疾患
  • 心疾患
  • 嚢胞性線維症
  • 非侵襲性出生前スクリーニング
  • 免疫疾患

第8章 バイオチップ産業

  • バイオチップ産業における買収
  • バイオチップ産業における戦略的提携
  • LOAC産業
  • 次世代シーケンシング機器産業
  • マイクロアレイ産業
  • バイオチップ診断産業
  • 農業
  • 中国のバイオチップ産業

第9章 バイオチップ市場

  • バイオチップ市場の成長推進因子
  • 世界のバイオチップ市場
  • DNAマイクロアレイ市場
  • プロテインマイクロアレイ市場
  • LOAC市場
  • NGS市場
  • バイオチップ市場:地域別

第10章 バイオチップ特許

  • マイクロアレイ
  • LOAC
  • 次世代シーケンシング

第11章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO049F

The global market for biochip products reached nearly $3.9 billion in 2014. This market is projected to grow from $4.7 billion in 2015 to $18.4 billion in 2020, representing a compound annual growth rate (CAGR) of 31.6% between 2015 and 2020.

This report provides:

  • An overview of the global market for current and emerging biochip technologies.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Characterizations of biochip markets by type (DNA microarray, protein microarray, emerging microarray, and lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end-user (research-and-development tools, drug discovery and development, diagnostics, sequencing, and applied).
  • A focused study on the market for biochip-based diagnostics products, a major future segment for biochips.
  • Discussion of the main commercial biochip technologies and the commercial potential of the key market segments.
  • Examination of the factors that influence the market, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, and customer needs.
  • Patent analysis.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE AND FORMAT OF REPORT

The study scope includes the major biochip platforms, including DNA and protein microarrays, tissue/cell and glycomics microarrays, LOAC products and NGS. Each platform is analyzed to determine its market status, impact on future market segments, and forecast growth from 2015 through 2020. Technology status and market driving forces are discussed, as well as influencing market factors like industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.

In addition to the main LOAC, microarray and sequencing industries, BCC Research profiles several specialized biochip industry segments including the following: DNA analyzers, ion channel screening, digital PCR, label-free detection, nanoarray, peptide microarray, antibody microarray, antibody reagents, multiplex protein diagnostics, circulating tumor cell, prenatal screening, point of care CD4 counting and China's biochips industries.

Applications for biochips-based diagnostics are highlighted in this report - particularly cancer diagnostics - as well as new data about biochip substrate types.

This BCC Research report also analyzes patent data for each biochip type. The industry has grown significantly since the last report, and nearly 300 companies are profiled in our analysis.

The table below highlights the scope of this report and identifies areas that were not analyzed.

A SCOPE OF REPORT

Covered in Report Not Covered in Report
DNA microarrays Bioinformatics
Protein microarrays Services
Tissue/cell and glycomics microarrays Chemical reagents
LOAC, including NGS Instruments

Source: BCC Research

Not included in the report are bioinformatics products and revenues and service revenues associated with biochips and chemical reagents associated microarrays and LOAC devices.

ANALYST'S CREDENTIALS

Jon Evans has been involved in business development and research for the medical industry since 1984. Mr. Evans' career includes four years as a diagnostic systems sales representative and more than 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a B.S. in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE AND FORMAT OF REPORT
  • TABLE A SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET TRENDS FOR BIOCHIP PRODUCTS BY END USE, 2014-2020 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • INTRODUCTION
  • TABLE 1 BIOLOGY DOWNSIZING REVOLUTION
  • BIOCHIP TYPES
  • TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES
  • TABLE 3 BIOCHIP NOMENCLATURE
  • MARKET POTENTIAL OF BIOCHIPS
  • TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2020 ($ MILLIONS)
  • DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS
  • TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH
  • THE BIOCHIP INDUSTRY
  • TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES

CHAPTER 4 MICROARRAY TECHNOLOGIES

  • INTRODUCTION
  • TABLE 7 THE NANOSCALE WORLD
  • TABLE 8 TYPES OF MICROARRAY
  • TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES
  • DNA MICROARRAY TECHNOLOGIES
    • DNA MICROARRAY TYPES
    • FIGURE 1 MICROARRAY FEATURE DENSITY
    • FIGURE 2 MICROARRAY RESOLUTION
    • TABLE 10 MICROARRAY GENOME CONTENT
    • TABLE 11 DNA MICROARRAY PLATFORM FEATURES
    • DNA MICROARRAY APPLICATIONS
    • TABLE 12 APPLICATIONS OF DNA MICROARRAY
    • TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES
    • FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1
    • SNP ANALYSIS
    • TABLE 14 SNP MEASUREMENT PLATFORMS
    • EPIGENETIC ANALYSIS
    • FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS`
    • CYTOGENETIC ANALYSIS
    • TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES
    • MICRO-RNA ANALYSIS
    • TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT
    • BEAD-BASED ARRAYS
    • TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS
    • CATALOG AND CUSTOM DNA MICROARRAYS
    • PROTEIN MICROARRAY TECHNOLOGIES
    • INTRODUCTION
    • FIGURE 5 IMPORTANCE OF PROTEINS
    • PROTEOMICS WORKFLOW
    • FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED
    • PROTEIN MICROARRAY DESIGN FEATURES
    • TABLE 18 PROTEIN MICROARRAY PLATFORMS
    • PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS
    • TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS
    • PROTEIN MICROARRAY TYPES
    • TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY
    • PROTEIN MICROARRAY TECHNOLOGY CHALLENGES
    • TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY
  • EMERGING MICROARRAY TECHNOLOGIES
  • TABLE 22 EMERGING MICROARRAY TECHNOLOGIES
    • GLYCOMICS MICROARRAYS
    • TISSUE MICROARRAYS

CHAPTER 5 LAB-ON-A-CHIP TECHNOLOGIES

  • INTRODUCTION
  • TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE
  • SUBSTRATE MATERIALS
  • TABLE 24 BIOCHIPS SUBSTRATE MATERIALS
  • LOAC TYPES
  • TABLE 25 TYPES OF LOAC
    • IN VITRO PROTEOMICS
    • ELECTROPHORESIS ON A CHIP
    • STRUCTURAL PROTEOMICS
    • PCR ON A CHIP
    • IMMUNOASSAY ON A CHIP
    • MASS SPECTROMETRY ON CHIP
    • NEXT-GENERATION SEQUENCING ON CHIP
    • TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS
    • TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES
  • LOAC APPLICATIONS
  • TABLE 28 SEGMENTS OF LOAC MARKET
  • TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS
  • ORGAN ON CHIP
  • LOAC TECHNOLOGY CHALLENGES
  • TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY

CHAPTER 6 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS

  • INTRODUCTION
  • TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS
  • DRUG INDUSTRY CHALLENGES
  • DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE
  • TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
    • DRUG TARGET IDENTIFICATION
    • DRUG DISCOVERY
      • Structural Biology
      • Lead Generation
      • Lead Optimization
      • Process R&D
      • Preclinical and Clinical Trials
  • NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT
  • FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS

CHAPTER 7 DIAGNOSTICS APPLICATIONS

  • INTRODUCTION
  • TABLE 34 DIAGNOSTICS PARADIGM SHIFT
  • HOW DIAGNOSTICS DIFFER FROM RESEARCH TOOLS
  • TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY
  • HOW BIOLOGICAL CONTENT DRIVES THE GROWTH OF DIAGNOSTICS
  • TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS
  • FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS
  • TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS
  • MOLECULAR DIAGNOSTICS
    • INTRODUCTION
    • MARKET CHALLENGES FOR DNA-BASED MDX PLATFORMS
    • TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS
    • TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET
  • DIAGNOSTICS MARKET SEGMENTS
  • TEST SENSITIVITY AND SPECIFICITY
  • FIGURE 9 SENSITIVITY AND SPECIFICITY
  • REGULATORY STATUS
  • BIOCHIPS CANCER APPLICATIONS
    • CANCER OVERVIEW
    • TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012
    • BLADDER CANCER
    • TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS
    • BREAST CANCER
      • Breast Cancer Screening
      • Prognosis and Pharmacogenetics Tests
      • TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION
      • Breast Cancer MDx Platforms
      • TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS
      • TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS
    • CERVICAL CANCER
    • TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS
    • COLORECTAL CANCER
      • Conventional Colorectal Cancer Screening Tests
      • TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER
      • Molecular Colorectal Cancer Diagnostics Tests
      • TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS
    • CANCER OF UNKNOWN PRIMARY (CUP)
    • TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP
    • KIDNEY CANCER
    • TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS
    • LEUKEMIA
    • TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS
    • LIVER CANCER
    • TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS
    • LYMPHOMA
    • TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS
    • LUNG CANCER
    • TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)
    • TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS
    • MELANOMA
    • TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS
    • OVARIAN CANCER
    • TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER
    • TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS
    • PANCREATIC CANCER
    • TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS
    • PROSTATE CANCER
    • TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS
    • THYROID CANCER
    • TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS
    • SUMMARY OF ADVANCED CANCER DIAGNOSTICS
    • TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND
    • TECHNOLOGY
  • WARFARIN SENSITIVITY
  • TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%)
  • TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS
  • INFECTIOUS DISEASES
    • TUBERCULOSIS
    • HOSPITAL-ACQUIRED INFECTIONS
    • TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS
    • INFLUENZA
    • TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS
    • SEXUALLY TRANSMITTED DISEASES
    • TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS
    • OTHER INFECTIOUS DISEASES
  • NEUROLOGICAL
    • ALZHEIMER'S DISEASE
    • TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE
    • TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS
    • SCHIZOPHRENIA
  • CARDIAC DISORDERS
    • CONGESTIVE HEART FAILURE
    • TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE
  • CYSTIC FIBROSIS
  • TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS
  • NONINVASIVE PRENATAL SCREENING
  • TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY
  • IMMUNE DISORDERS
    • HLA TYPING
    • TABLE 72 HLA TESTING MARKET
    • AUTOIMMUNE TESTING

CHAPTER 8 BIOCHIPS INDUSTRY

  • BIOCHIPS INDUSTRY ACQUISITIONS, 2012 TO 2015
  • TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015
  • BIOCHIPS INDUSTRY STRATEGIC ALLIANCES
    • MICROARRAY INDUSTRY STRATEGIC ALLIANCES
    • TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013
    • LOAC INDUSTRY STRATEGIC ALLIANCES
    • TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013
  • LOAC INDUSTRY
    • LOAC INDUSTRY OVERVIEW
    • TABLE 76 LOAC COMPETITOR LANDSCAPE
    • LOAC INSTRUMENT INDUSTRY
    • TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS
    • LOAC DNA ANALYZER INDUSTRY
    • TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS
    • LOAC DIAGNOSTICS INDUSTRY
    • TABLE 79 LOAC DIAGNOSTICS INDUSTRY
    • ION CHANNEL SCREENING INDUSTRY
    • TABLE 80 ION CHANNEL SCREENING INDUSTRY
    • DIGITAL PCR INDUSTRY
    • TABLE 81 DIGITAL PCR INDUSTRY
    • INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY
    • TABLE 82 LOAC UNIVERSITY SPIN-OFFS
    • ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY
    • TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES
  • NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY
  • TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE
  • MICROARRAY INDUSTRY
    • SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY
    • TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY
    • LABEL-FREE DETECTION INDUSTRY
    • TABLE 86 LABEL-FREE DETECTION INDUSTRY
    • NANOARRAY INDUSTRY
    • TABLE 87 NANOARRAY INDUSTRY
    • PEPTIDE MICROARRAY INDUSTRY
    • TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES
    • ANTIBODY MICROARRAY INDUSTRY
    • TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES
    • ANTIBODY REAGENTS INDUSTRY
    • TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES, 2012
  • BIOCHIPS DIAGNOSTICS INDUSTRY
    • MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY
    • TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES
    • CIRCULATING TUMOR CELL INDUSTRY
    • TABLE 92 CTC BIOCHIPS INDUSTRY
    • PRENATAL DIAGNOSTICS INDUSTRY
    • TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 ($)
    • TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%)
    • TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS
    • POC CD4 COUNTING INDUSTRY
    • TABLE 96 POC CD4 INDUSTRY
  • AGRICULTURAL INDUSTRY
  • TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY
  • CHINA'S BIOCHIP INDUSTRY
  • TABLE 98 CHINA BIOCHIP INDUSTRY

CHAPTER 9 BIOCHIPS MARKETS

  • DRIVING FORCES FOR BIOCHIPS GROWTH
  • TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS
  • GLOBAL BIOCHIPS MARKET
  • TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
  • TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • DNA MICROARRAY MARKETS
    • DNA MICROARRAY MARKET BY END-USE INDUSTRY
    • TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
    • DNA MICROARRAY MARKET BY ANALYSIS TYPE
    • TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE, 2015 (%)
    • FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2014 (NO.)
    • DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL
    • TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • PROTEIN MICROARRAYS MARKETS
    • INTRODUCTION
    • TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY
    • PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY
    • TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
    • PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL
    • TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
    • TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL
    • PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE
    • TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015 (%)
    • EMERGING MICROARRAYS MARKETS
    • EMERGING MICROARRAYS MARKET BY TECHNOLOGY
    • TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015 (%)
    • EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY
    • TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
    • EMERGING ARRAYS MARKET BY SUBSTRATE TYPE
    • TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • LOAC MARKETS
    • GENOMICS LOAC MARKET BY END-USE INDUSTRY
    • TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
    • GENOMICS LOAC MARKET BY SUBSTRATE TYPE
    • TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
    • PROTEOMICS LOAC MARKET BY END-USE INDUSTRY
    • TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
    • PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE
    • TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • NGS MARKETS
    • NGS MARKETS BY END-USER INDUSTRY
    • TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
    • NGS MARKET BY SUBSTRATE TYPE
    • TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
    • NGS MARKETS BY TEST COMPLEXITY
    • TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%)
    • BIOCHIPS DIAGNOSTICS MARKETS
    • INTRODUCTION
    • DIAGNOSTICS MARKET BY BIOCHIP TYPE
    • TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS
    • DIAGNOSTICS MARKET BY INDICATION
    • TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION, 2015 (%)
    • DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL
    • TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, 2015 (%)
    • CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE
    • TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, 2015 (%)
    • CANCER DIAGNOSTICS MARKET BY INDICATION
    • TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY INDICATION, 2015 (%)
    • TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS, 2015
  • BIOCHIPS MARKETS BY REGION 243
    • REGIONAL MARKET SUMMARY 243
    • TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 ($ MILLIONS)
    • MICROARRAY MARKET BY REGION
    • TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • LOAC MARKET BY REGION
    • TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 ($ MILLIONS)
    • NGS MARKET BY REGION
    • TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 10 BIOCHIPS PATENTS

  • MICROARRAY PATENTS
  • TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND TITLE,2013-2015
  • LOAC PATENTS
  • TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 137 LOAC-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015
  • CLINICAL NEXT-GENERATION SEQUENCING PATENTS
    • CLINICAL NGS PATENTS SUMMARY
    • TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 (NO.)
    • TABLE 139 CLINICAL NGS-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015
    • CLINICAL NGS PATENTS BY INDICATION
    • TABLE 140 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012 (NO.)

CHAPTER 11 COMPANY PROFILES

  • 3QBD
  • 20/20 GENE SYSTEMS INC.
  • ABAXIS INC.
  • ABBOTT LABORATORIES
  • ABIONIC SA
  • ABTECH SCIENTIFIC INC.
  • ABACUS DIAGNOSTICA LTD.
  • ACCELERATE DIAGNOSTICS INC.
  • ACEA BIOSCIENCES INC.
  • ACHIRA LABS PVT. LTD.
  • ADVANCED LIQUID LOGIC
  • AFFYMETRIX INC.
  • AGENDIA BV
  • TABLE 141 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE
  • AGENIX LTD.
  • AGILENT TECHNOLOGIES INC.
  • AKONNI BIOSYSTEMS
  • TABLE 142 AKONNI BIOCHIP GRANTS
  • ALERE TECHNOLOGIES GMBH
  • ALLEGRO DIAGNOSTICS CORP.
  • ALMAC GROUP, LTD.
  • ANALYTIK JENA AG
  • AQUAMARIJIN MICRO FILTRATION BV
  • AQUILA DIAGNOSTIC SYSTEMS INC.
  • ARRAYIT CORPORATION
  • ASSURERX HEALTH INC.
  • ATONOMICS A/S
  • AUSHON BIOSYSTEMS INC.
  • AUTOGENOMICS INC.
  • AVACTA GROUP PLC
  • AVIANA MOLECULAR TECHNOLOGIES
  • AXELA INC.
  • AYOXXA BIOSYSTEMS GMGH
  • BECKMAN COULTER INC.
  • BECTON, DICKINSON AND CO.
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODOT INC.
  • BIOFIRE DIAGNOSTICS INC.
  • BIOFLUIDIX GMBH
  • BIOFORCE NANOSCIENCES INC.
  • BIOMERIEUX SA
  • BIONANOGENOMICS INC.
  • BIORAD LABORATORIES INC.
  • BIOSCALE INC.
  • BIOSURFIT SA
  • BIOSYSTEMS INTERNATIONAL
  • BIOTRAY
  • BLUE4GREEN
  • BODITECH MED INC.
  • BOEHRINGER INGELHEIM MICROPARTS GMBH
  • BOSTON MICROFLUIDICS
  • CAMBRIDGE BIOMAGNETICS LTD.
  • CANCER GENETICS INC.
  • CAPITALBIO CORPORATION
  • CARIS LIFE SCIENCES
  • CBC COMPREHENSIVE BIOMARKER CENTER GMBH
  • CELLANYX DIAGNOSTICS INC.
  • CELLASIC
  • CELLECTRICON AB
  • CELLIX, LTD.
  • CELLSCAPE CORPORATION
  • CELLULAR RESEARCH INC.
  • CELULA INC.
  • CEPHEID
  • CLEARBRIDGE BIOMEDICS
  • COMBIMATRIX MOLECULAR DIAGNOSTICS INC.
  • COURTAGEN LIFE SCIENCES INC.
  • CREATIVE MICROSYSTEMS CORPORATION
  • CUSTOMARRAY INC.
  • CYBRDI INC.
  • CYCLOFLUIDIC LTD.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOCENTRICS BIOSCIENCE
  • CYTOO SA
  • DEBIOTECH S.A.
  • DELTADOT LTD.
  • DEOS LABS
  • DIAGENIC ASA
  • DIAGNOSTICS FOR ALL
  • DIAGNOSWISS S.A.
  • DIAXONHIT
  • DNA ELECTRONICS LTD.
  • DNA LINK INC.
  • DNAMICROARRAY INC.
  • DOLOMITE MICROFLUIDICS LTD.
  • DR. CHIP BIOTECH INC.
  • DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH
  • DYCONEX AG
  • EKSIGENT
  • ELVEFLOW
  • ELIM BIOPHARMACEUTICALS INC.
  • EMULATE INC.
  • EPIGEM LTD.
  • EPOCAL INC.
  • EUROIMMUN AG
  • FALCON GENOMICS INC.
  • FLUIDIGM CORPORATION
  • FLUIDWARE TECHNOLOGIES INC.
  • FLUIMEDIX APS
  • FLUXION BIOSCIENCES INC.
  • FULL MOON BIOSYSTEMS INC.
  • GEN9 INC.
  • GENALYTE
  • GENEFLUIDICS, INC.
  • GENENEWS
  • GENEPOC INC.
  • GENMARK DIAGNOSTICS, INC.
  • GENOMEDX BIOSCIENCES INC.
  • GENOMICA SAU
  • GIGAGEN INC.
  • GNUBIO INC.
  • GOOD START GENETICS INC.
  • GRACE BIO LABS
  • GRADIENTECH AB
  • GWC TECHNOLOGIES INC.
  • GYROS AB
  • HNU-NANOPOINT
  • HOLOGIC INC.
  • ILLUMINA, INC.
  • IMMUNOVIA AB
  • INANOVATE INC.
  • INDX LIFECARE
  • INNOSIEVE DIAGNOSTICS BV
  • INSTITUTE OF MICROCHEMICAL TECHNOLOGY CO. LTD.
  • INTAVIS BIOANALYTICAL INSTRUMENTS AG
  • INTEL CORPORATION
  • IQUUM INC.
  • IRIS BIOTECHNOLOGIES INC.
  • ISU ABXIS CO. LTD.
  • JOHNSON & JOHNSON
  • JPT PEPTIDE TECHNOLOGIES GMBH
  • KINEXUS BIOINFORMATICS CORPORATION
  • LAB21 LTD.
  • LABORATORY CORPORATION OF AMERICA INC.
  • LC SCIENCES
  • LEUKODX LTD.
  • LIFE TECHNOLOGIES INC.
  • LINEAGEN INC.
  • LIONIX BV
  • LUMINEX
  • MAGARRAY, INC.
  • MAXWELL SENSORS INC.
  • MEDIMATE BV
  • MERCK KGAA
  • METAMARK GENETICS INC.
  • MICRO2GEN LTD.
  • MICROCHIPS INC.
  • MICRODISH BV
  • MICRODROP TECHNOLOGIES GMBH
  • MICROFAB TECHNOLOGIES INC.
  • MICROFLEXIS GMBH
  • MICROFLUIDIC CHIPSHOP GMBH
  • MICROFLUIDIC INNOVATIONS LLC
  • MICROFLUIDIX INC.
  • MICROLIQUID
  • MICROLYTIC
  • MICRONICS MICROFLUIDICS
  • MICRONIT MICROFLUIDICS BV
  • MICROPOINT BIOSCIENCES INC.
  • MICRUX TECHNOLOGIES SA
  • MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD.
  • MOBIDIAG OY/LTD.
  • MODE DX LTD.
  • MOLECULAR CYTOMICS INC.
  • MYCROARRAY INC.
  • MYCROLAB DIAGNOSTICS PTY LTD.
  • NANION TECHNOLOGIES GMBH
  • NANO TERRA INC.
  • NANOBIOSYM
  • NANOBIOSYS
  • NANOCELLECT BIOMEDICAL INC.
  • NANOENTEK INC.
  • NANOIVD INC.
  • NANOMI BV
  • NANOMIX INC.
  • NANOSPEED DIAGNOSTICS INC.
  • NANOSPHERE INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NEC CORPORATION
  • NEOGEN CORPORATION
  • NEOGENOMICS LABORATORIES
  • NETBIO INC.
  • NEXUS DX INC.
  • NOVARTIS
  • NUCLEA BIOTECHNOLOGIES INC.
  • OPKO HEALTH INC.
  • OPTOTRACK INC.
  • OSMOTEX AG
  • OSTENDUM R&D BV
  • OXFORD GENE TECHNOLOGY
  • PAMGENE INTERNATIONAL BV
  • PATHGEN DX PTE LTD.
  • PATHOGENETIX INC.
  • PATHOGENICA
  • PEPPERPRINT GMBH
  • PEPSCAN PRESTO BV
  • PERKINELMER
  • PHALANX BIOTECH GROUP
  • PHILIPS ELECTRONICS NV
  • PLEXERA LLC
  • POSITIVE ID CORPORATION
  • PROTAGEN AG
  • PROTEIN BIOTECHNOLOGIES INC.
  • PROTEUS DIGITAL HEALTH INC.
  • PROTNETEOMIX SAS
  • QIAGEN
  • Q-LINEA AB
  • QUANTERIX CORPORATION
  • QUANTISCIENTIFICS LLC
  • QUANTUM DX
  • QUEST DIAGNOSTICS
  • QWANE BIOSCIENCES S.A
  • RAINDANCE TECHNOLOGIES INC.
  • RANDOX LABORATORIES LTD.
  • RAYBIOTECH INC.
  • RETROGENIX LTD.
  • RHEONIX
  • RHEOSENSE INC.
  • RIDGE DIAGNOSTICS INC.
  • ROCHE HOLDING AG
  • ROSETTA GENOMICS INC.
  • TABLE 143 ROSETTA'S DIAGNOSTICS TESTS
  • SAMSUNG ELECTRONICS CO. LTD.
  • SANDSTONE DIAGNOSTICS INC.
  • SAVYON DIAGNOSTICS LTD.
  • SCIENION AG
  • SEEGENE INC.
  • TABLE 144 SEEGENE BIOCHIPS COLLABORATIONS
  • SENGENICS INTERNATIONAL PTE LTD
  • SENSIMED AG
  • SENSLAB GMBH
  • SENZAIR B.V.
  • SFC FLUIDICS LLC
  • SHANGHAI BIOCHIP CO. LTD.
  • SHANGHAI HUAGUAN BIOCHIP CO. LTD.
  • SHARP CORPORATION
  • SIAMAB THERAPEUTICS INC.
  • SIGNAL GENETICS LLC
  • SIGNATURE DIAGNOSTICS AG
  • SILICON BIOSYSTEMS
  • SILOAM BIOSCIENCES INC.
  • SKYLINEDX
  • SLIPCHIP LLC
  • SOMALOGIC INC.
  • SOPHION BIOSCIENCE (BIOLIN SCIENTIFIC)
  • SPARTAN BIOSCIENCES INC.
  • SPHERE FLUIDICS LIMITED
  • SPHERE MEDICAL LTD.
  • SPINCHIP DIAGNOSTICS AS
  • SPINOMIX
  • SQI DIAGNOSTICS, INC.
  • SURMODICS INC.
  • SURNETICS
  • SYSMEX INOSTICS
  • T2 BIOSYSTEMS
  • TEARLAB CORPORATION
  • TECAN GROUP LTD.
  • THERMO FISHER SCIENTIFIC INC.
  • THINXXS MICROTECHNOLOGY AG
  • TIANJIN BIOCHIP CORPORATION
  • TIRF LABS INC.
  • TRANSGENOMIC INC.
  • TRANSLUME INC.
  • TRINEAN NV
  • TRINITY BIOTECH PLC
  • TROVAGENE INC.
  • US BIOMAX INC.
  • VERACYTE INC.
  • VEREDUS LABORATORIES PTE LTD.
  • WAFERGEN BIOSYSTEMS INC.
  • WASATCH MICROFLUIDICS
  • WAVE 80 BIOSCIENCES
  • WUXI BUOSHENG BIO-ENGINEERING CO. LTD.
  • XAGENIC INC.
  • XONA MICROFLUIDICS LLC
  • YMC CO. LTD.
  • ZELLKRAFTWERK GMBH
  • ZYOMYX, INC.
  • ZYOXEL LTD.

LIST OF TABLES

  • TABLE A SCOPE OF REPORT
  • SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 BIOLOGY DOWNSIZING REVOLUTION
  • TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES
  • TABLE 3 BIOCHIP NOMENCLATURE
  • TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH
  • TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES
  • TABLE 7 THE NANOSCALE WORLD
  • TABLE 8 TYPES OF MICROARRAY
  • TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES
  • TABLE 10 MICROARRAY GENOME CONTENT
  • TABLE 11 DNA MICROARRAY PLATFORM FEATURES
  • TABLE 12 APPLICATIONS OF DNA MICROARRAY
  • TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES
  • TABLE 14 SNP MEASUREMENT PLATFORMS
  • TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES
  • TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT
  • TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS
  • TABLE 18 PROTEIN MICROARRAY PLATFORMS
  • TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS
  • TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY
  • TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY
  • TABLE 22 EMERGING MICROARRAY TECHNOLOGIES
  • TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE
  • TABLE 24 BIOCHIPS SUBSTRATE MATERIALS
  • TABLE 25 TYPES OF LOAC
  • TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA SEQUENCING PLATFORMS
  • TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES
  • TABLE 28 SEGMENTS OF LOAC MARKET
  • TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS
  • TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY
  • TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS
  • TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
  • TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT
  • TABLE 34 DIAGNOSTICS PARADIGM SHIFT
  • TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY
  • TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS
  • TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS
  • TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS
  • TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS INTO THE MDX MARKET
  • TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012
  • TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS
  • TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION
  • TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS
  • TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS
  • TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS
  • TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER
  • TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS
  • TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP
  • TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS
  • TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS
  • TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS
  • TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS
  • TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)
  • TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS
  • TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS
  • TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER
  • TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS
  • TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS
  • TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS
  • TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS
  • TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND TECHNOLOGY
  • TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%)
  • TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS
  • TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS
  • TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS
  • TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS
  • TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE
  • TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS
  • TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE
  • TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS
  • TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY
  • TABLE 72 HLA TESTING MARKET
  • TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015
  • TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013
  • TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013
  • TABLE 76 LOAC COMPETITOR LANDSCAPE
  • TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS
  • TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS
  • TABLE 79 LOAC DIAGNOSTICS INDUSTRY
  • TABLE 80 ION CHANNEL SCREENING INDUSTRY
  • TABLE 81 DIGITAL PCR INDUSTRY
  • TABLE 82 LOAC UNIVERSITY SPIN-OFFS
  • TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES
  • TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE
  • TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY
  • TABLE 86 LABEL-FREE DETECTION INDUSTRY
  • TABLE 87 NANOARRAY INDUSTRY
  • TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES
  • TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES
  • TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES, 2012
  • TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES
  • TABLE 92 CTC BIOCHIPS INDUSTRY
  • TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 ($)
  • TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%)
  • TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS
  • TABLE 96 POC CD4 INDUSTRY
  • TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY
  • TABLE 98 CHINA BIOCHIP INDUSTRY
  • TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS
  • TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
  • TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
  • TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE, 2015 (%)
  • TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY
  • TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
  • TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL
  • TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015 (%)
  • TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015 (%)
  • TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020 ($ MILLIONS)
  • TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY, THROUGH 2020 ($ MILLIONS)
  • TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020 ($ MILLIONS)
  • TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%)
  • TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS
  • TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION, 2015 (%)
  • TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL, 2015 (%)
  • TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE, 2015 (%)
  • TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY INDICATION, 2015 (%)
  • TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER APPLICATIONS, 2015
  • TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND TITLE,2013-2015
  • TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.)
  • TABLE 137 LOAC-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015
  • TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 (NO.)
  • TABLE 139 CLINICAL NGS-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015
  • TABLE 140 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012 (NO.)
  • TABLE 141 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE
  • TABLE 142 AKONNI BIOCHIP GRANTS
  • TABLE 143 ROSETTA'S DIAGNOSTICS TESTS
  • TABLE 144 SEEGENE BIOCHIPS COLLABORATIONS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET TRENDS FOR BIOCHIP PRODUCTS BY END USE, 2014-2020 ($ MILLIONS)
  • FIGURE 1 MICROARRAY FEATURE DENSITY
  • FIGURE 2 MICROARRAY RESOLUTION
  • FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1
  • FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS`
  • FIGURE 5 IMPORTANCE OF PROTEINS
  • FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED
  • FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE
  • FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS
  • FIGURE 9 SENSITIVITY AND SPECIFICITY
  • FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2014 (NO.)
Back to Top